The Impact of Social Distancing in 2020 on Admission Rates for Exacerbations in Asthma: A Nationwide Cohort Study.
Asthma
Epidemiology
Exacerbations
Lockdown
Social distancing
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
13
02
2022
revised:
08
04
2022
accepted:
13
04
2022
pubmed:
3
5
2022
medline:
17
8
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
Social distancing measures introduced during the coronavirus disease 2019 pandemic have reduced admission rates for various infectious and noninfectious respiratory diseases. We hypothesized that rates of asthma exacerbations would decline following the national lockdown in Denmark. To determine weekly rates of in- and out-of-hospital asthma exacerbations before and during the social distancing intervention implemented on March 12, 2020. All individuals older than 18 years with at least 1 outpatient hospital contact with asthma as the main diagnosis from January 1, 2013, to December 31, 2017, were included. Weekly asthma exacerbation rates from January 1, 2018, to May 22, 2020, were calculated. An interrupted time-series model with the lockdown on March 12, 2020, as the point of interruption was used. A total of 38,225 patients with asthma were identified. The interrupted time-series model showed no immediate fall in exacerbation rates during the first week after March 12, 2020. However, there was a significant decline in weekly exacerbation rates in the following 10 weeks (change in trend for exacerbations requiring hospitalization: -0.75 [95% CI, -1.39 to -0.12]; P < .02 and in all asthma exacerbations: -12.2 [95% CI, -19.1 to -5.4; P < .001), amounting to a reduction of approximately 1 and 16.5 exacerbations per year per 100 patients in the cohort, respectively. The introduction of the social distancing measures in Denmark did not lead to an immediate reduction in asthma exacerbation rates; however, a gradual decline in exacerbation rates during the following 10-week period was observed.
Sections du résumé
BACKGROUND
Social distancing measures introduced during the coronavirus disease 2019 pandemic have reduced admission rates for various infectious and noninfectious respiratory diseases. We hypothesized that rates of asthma exacerbations would decline following the national lockdown in Denmark.
OBJECTIVE
To determine weekly rates of in- and out-of-hospital asthma exacerbations before and during the social distancing intervention implemented on March 12, 2020.
METHODS
All individuals older than 18 years with at least 1 outpatient hospital contact with asthma as the main diagnosis from January 1, 2013, to December 31, 2017, were included. Weekly asthma exacerbation rates from January 1, 2018, to May 22, 2020, were calculated. An interrupted time-series model with the lockdown on March 12, 2020, as the point of interruption was used.
RESULTS
A total of 38,225 patients with asthma were identified. The interrupted time-series model showed no immediate fall in exacerbation rates during the first week after March 12, 2020. However, there was a significant decline in weekly exacerbation rates in the following 10 weeks (change in trend for exacerbations requiring hospitalization: -0.75 [95% CI, -1.39 to -0.12]; P < .02 and in all asthma exacerbations: -12.2 [95% CI, -19.1 to -5.4; P < .001), amounting to a reduction of approximately 1 and 16.5 exacerbations per year per 100 patients in the cohort, respectively.
CONCLUSIONS
The introduction of the social distancing measures in Denmark did not lead to an immediate reduction in asthma exacerbation rates; however, a gradual decline in exacerbation rates during the following 10-week period was observed.
Identifiants
pubmed: 35500879
pii: S2213-2198(22)00427-5
doi: 10.1016/j.jaip.2022.04.020
pmc: PMC9352355
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2086-2092.e2Informations de copyright
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Références
Clin Epidemiol. 2012;4:303-13
pubmed: 23204870
Pediatr Pulmonol. 2021 Oct;56(10):3166-3173
pubmed: 34289526
Am J Epidemiol. 2022 Mar 24;191(5):874-885
pubmed: 34999742
Lancet Respir Med. 2022 Jan;10(1):6-7
pubmed: 34895476
PLoS One. 2021 Aug 3;16(8):e0255659
pubmed: 34343205
Front Public Health. 2020 Dec 16;8:604089
pubmed: 33392141
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Respiration. 2020;99(12):1109-1121
pubmed: 33271561
BMJ Open Respir Res. 2021 May;8(1):
pubmed: 33952584
J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):1989-1998.e3
pubmed: 29627457
Respir Med. 2017 Feb;123:34-41
pubmed: 28137494
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):759-67
pubmed: 25439368
Lancet. 2010 Sep 4;376(9743):826-34
pubmed: 20816549
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2384-2385
pubmed: 32371047
N Engl J Med. 2021 May 13;384(19):1800-1809
pubmed: 33979488
BMC Med Res Methodol. 2021 Mar 22;21(1):58
pubmed: 33752604
Eur Respir J. 2011 May;37(5):1037-42
pubmed: 20693244
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Eur Heart J. 2021 Apr 14;42(15):1516-1523
pubmed: 33624011
Eur Respir J. 2014 Dec;44(6):1666-81
pubmed: 25234802
Lancet. 2016 Oct 29;388(10056):2128-2141
pubmed: 27609406
N Engl J Med. 2020 Jul 23;383(4):400-401
pubmed: 32383831
Thorax. 2021 Sep;76(9):860-866
pubmed: 33782080
BMC Public Health. 2012 Mar 19;12:204
pubmed: 22429515
JAMA Netw Open. 2021 Feb 1;4(2):e2037227
pubmed: 33576819